
Brazil · Business Key Facts —Patent expiry Novo Nordisk’s semaglutide patent expired in March 2026, ending exclusivity for Ozempic and Wegovy in Brazil. —New registrations Anvisa registered five new semaglutide pens on July 29, 2026…
View original source — Rio Times ↗

